CASIA OpenIR  > 中国科学院分子影像重点实验室
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Song, Jiangdian1,2,3; Shi, Jingyun4; Dong, Di1,5; Fang, Mengjie1,5; Zhong, Wenzhao6; Wang, Kun1,5; Wu, Ning7,8; Huang, Yanqi9; Liu, Zhenyu1,5; Cheng, Yue10; Gan, Yuncui10; Zhou, Yongzhao10; Zhou, Ping10; Chen, Bojiang10; Liang, Changhong9; Liu, Zaiyi9; Li, Weimin10; Tian, Jie1,5,11
2018-08-01
发表期刊CLINICAL CANCER RESEARCH
卷号24期号:15页码:3583-3592
文章类型Article
摘要Purpose: We established a CT-derived approach to achieve accurate progression-free survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter, stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients.
WOS标题词Science & Technology ; Life Sciences & Biomedicine
DOI10.1158/1078-0432.CCR-17-2507
关键词[WOS]CELL LUNG-CANCER ; TYROSINE KINASE INHIBITORS ; OPEN-LABEL ; ACQUIRED-RESISTANCE ; PHASE-III ; 1ST-LINE ERLOTINIB ; MUTATIONS ; CHEMOTHERAPY ; TRIAL ; MULTICENTER
收录类别SCI
语种英语
项目资助者Natural Science Foundation of China(81771924 ; National Key R&D Program of China(2017YFA0205200 ; Science and Technology Service Network Initiative of the Chinese Academy of Sciences(KFJ-SW-STS-160) ; Instrument Developing Project of the Chinese Academy of Sciences(YZ201502) ; Beijing Municipal Science and Technology Commission(Z171100000117023 ; Youth Innovation Promotion Association CAS ; 81501616 ; 2017YFC1308700 ; Z161100002616022) ; 61671449 ; 2017YFC1308701 ; 61231004 ; 2017YFC1309100) ; 81671854 ; 81501549)
WOS研究方向Oncology
WOS类目Oncology
WOS记录号WOS:000440600200014
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/21847
专题中国科学院分子影像重点实验室
作者单位1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China
2.China Med Univ, Sch Med Informat, Shenyang, Liaoning, Peoples R China
3.Northeastern Univ, Sino Dutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China
4.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China
5.Univ Chinese Acad Sci, Beijing, Peoples R China
6.Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
7.Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, PET CT Ctr, Beijing, Peoples R China
8.Peking Union Med Coll, Beijing, Peoples R China
9.Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Radiol, Guangzhou, Guangdong, Peoples R China
10.West China Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China
11.Beijing Key Lab Mol Imaging, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Song, Jiangdian,Shi, Jingyun,Dong, Di,et al. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy[J]. CLINICAL CANCER RESEARCH,2018,24(15):3583-3592.
APA Song, Jiangdian.,Shi, Jingyun.,Dong, Di.,Fang, Mengjie.,Zhong, Wenzhao.,...&Tian, Jie.(2018).A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.CLINICAL CANCER RESEARCH,24(15),3583-3592.
MLA Song, Jiangdian,et al."A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy".CLINICAL CANCER RESEARCH 24.15(2018):3583-3592.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Song, Jiangdian]的文章
[Shi, Jingyun]的文章
[Dong, Di]的文章
百度学术
百度学术中相似的文章
[Song, Jiangdian]的文章
[Shi, Jingyun]的文章
[Dong, Di]的文章
必应学术
必应学术中相似的文章
[Song, Jiangdian]的文章
[Shi, Jingyun]的文章
[Dong, Di]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。